Bergenstal, 1952; Luft, Olivecrona, and Sjogren, 1W). The remission rates achieved by these various mnehods of treatment are remarkably similar; appronimately one third of tumours have a beneficial Vponse. Although in most patients the effects ar*short lived, in some they are prolonged and well nigh dtamatic.
considered to be oestrogen, adrenocortical steroids, and growth hormone. For full lobulo-alveolar development, equivalent to that at the termination of pregnancy, oestrogen, progesterone, prolactin, and growth hormone; and for the initiation of lactation, prolactin, growth hormone, and cortisol. In effect all the hormones shown in fig I have It was accepted for many years that only the ovarian hormones, oestrogen and progesterone, were concerned with normal growth of the breast. It is now appreciated that even the simplest form of growth, that of the duct system, cannot be stimulated in the absence of hormones of anterior pituitary origin. The formation of lobules, of alveoli and the production of milk demand even more complex hormonal influences.
As a result of studies in hypophysectomized, oophorectomized, and adrenalectomized rats these are now more clearly defined (Lyons, 1958; Lyons and Dixon, 1966; Cowie and Tindall, 1971 
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'promotion', the provision of conditions necessary for its continued growth and multiplication.
Apparently hormones can form the stimulus necessary for initiation or neoplastic transformation but only when given in unphysiologically large doses (Shimkin, 1958) . Their principal effect is to act as promoting agents. Yet there is overlap, for a suitable hormonal environment may still be a necessary prerequisite for tumour induction, irrespective of the stimulus. For example, removal of the source of oestrogens in female rats, before the administration of 7, 12-dimethylbenanthracene (DMBA), prevents tumour induction (Huggins, Briziarelli, and Sutton, 1959) . Conversely, intact male rats, normally refractory to the effects of DMBA, develop mammary tumours when provided with functioning ovarian grafts (Dao and Greiner, 1961) .
Early observations on spontaneous mammary cancer in mice, ie, that occurring in animals carrying the Bittner milk agent, indicated that the ovarian hormone oestrogen had a promoting role. Removal of the ovaries of female mice reduced its incidence whereas the grafting of functioning ovarian tissue or the administration of oestrogen to male mice, which normally do not develop spontaneous breast cancer, promoted tumour development (Lathrop and Loeb, 1916; Murray, 1928; Lacassagne, 1932) . Similar effects have been observed with carcinogeninduced tumours (Bonser, Dossett, and Jull, 1961) . There is evidence that the ovarian secretion of progesterone may also promote tumour development and when administered with oestrogen will further enhance its effect (Jull, 1954; Marchant, 1959; Bonser et al, 1961) .
Spontaneous mammary cancer in mice may also be influenced by pituitary hormones. The implantation of extra pituitaries, which by virtue of their separation from hypothalamic control secrete prolactin, or the induction of prolactin-secreting tumours of the pituitary by irradiation, increase its incidence (Loeb and Kirtz, 1939; Furth and Clifton, 1958) . Conversely hypophysectomy reduces it (Korteweg and Thomas, 1939) . Evidence that pituitary hormones are necessary for the promoting effect of oestrogens comes from the observation that hypophysectomy abolishes the high incidence of mammary carcinoma in oestrogen-treated mice, even if oestrogen treatment is continued after the operation (Lacassagne and Chamorro, 1939) . Forced breeding and pregnancies may also enhance the development of spontaneous mammary cancer in mice (Bonser et al, 1961) .
Recently emphasis has moved from mouse to rat as an experimental model, using the tumour aptly named after Huggins. These mammary tumours can most simply be induced by a single intragastric or A. P. M. Forrest intravenous pulse dose of DMBA in fat emulsion administered when the animal is 50 days of age. In suitable strains of Sprague-Dawley rats adenocarcinomas will develop in the majority of animals. in 60 to 100 days. As most of these tumours have the unique property of hormone dependence they are particularly suitable for studies of hormonal effects.
It is firmly established that oestrogens affect the growth of Huggins tumour and some believe that the tumour is primarily oestrogen dependent (Dao, 1962) . Removal of ovarian hormones by oophorectomy can induce regression, an effect which is reversible by their administration (Huggins et al, 1959; Sydnor and Cockrell, 1963; Young, Baker, and Helfenstein, 1965) . Regression of tumours also follows the administration of testosterone or 5-alpha-dihydrotestosterone, this effect also being reversed by oestrogen and progesterone (Huggins et al, 1959; Young et al, 1965) . The demonstration that oestrogen-receptor protein is present in the cells of the tumour and is related to their hormone sensitivity is further evidence that oestrogen is the prime hormone concerned (King, 1968; McGuire and Julian, 1971 ).
Yet there is now a growing belief that prolactin is equally, if not primarily, implicated. The induction of a high rate of prolactin secretion increases both their incidence and rate of growth (Clemens, Welsch, and Meites, 1968; Pearson, Llerena, Llerena, Molina, and Butler, 1969; Nagasawa and Meites, 1970) . As prolactin secretion from the pituitary is controlled by a hypothalamic inhibitory factor, hyperprolactinaemia can readily be achieved by lesions of the median eminence of the hypothalamus, by hypothalamic oestrogen implants, or by the administration of the phenothiazine group of drugs. It has also been shown that the administration of antiprolactin, prepared by immunization, will induce tumour regression (Butler and Pearson, 1972 ). Recently we have had an opportunity to study three strains of rats in our laboratory which have different incidences of mammary tumour following a single intravenous injection of 5 mg DMBA. Blood was collected during dioestrus from 11 rats in each strain and the concentration of prolactin estimated by radioimmunoassay . This was clearly correlated with tumour incidence (fig 2) .
The relationship between prolactin and oestrogen in stimulating tumour growth is further complicated by the finding that oestrogen, in all doses, stimulates prolactin secretion in the rat (Welsch and Meites, 1969 (Hadfield and Holt, 1956 ). Conversely enhancement of tumour growth has been observed during the ovarian cycle or as a result of the administration of oestrogen. j Increase in the size of soft tissue lesions and of pain and hypercalciuria from bone metastases has been observed during the premenstrual period (Raven, 1950; Kennedy, 1956; fig 4 (Mustacchi and Shimkin, 1957) ; and enhanced calciuria from bone metastases has been described following the administration of growth hormone and of prolactin * / (Pearson and Ray, 1959; McCalister et al, 1961) . No clear relationship has so far been observed between circulating hormone levels and the disease. A tendency for women with breast cancer to secrete more growth hormone in response to a glucose load has been described by Greenwood, James, * Meggitt, Miller, and Taylor (1968) and Pearson, Llerena, Samaan, and Gonzales (1968) , and recently * Murray, Mozaffarian, and Pearson (1972) have also reported increased levels of circulating prolactin in this disease. In our experience the growth hormone response to insulin hypoglycemia was normal in women with advanced malignancy of the breast (Stewart, Benson, Roberts, Forrest, and Greenwood, 1971) Wilson, and Forrest, 1973; Wilson et al, 1973) . Recent results using a homologous assay are shown in the table. Nor have we found any relationship between the effect of treatment on advanced breast cancer and the levels of circulating plasma prolactin. In fact remission of disease can occur in the face of increased prolactin secretion, even when the surgical procedure is pituitary stalk section (Turkington, Underwood, and Van Wyk, 1971 ).
Strangely, a stronger relationship has emerged between the levels of the metabolites of the C-19 (androgenic) steroids in the urine and human breast cancer. In a series of papers between 1960 and 1971, Bulbrook and his colleagues have suggested that abnormally low levels of urinary aetiocholanolone may confer an increased risk of breast cancer, a poor prognosis of established disease, and a low incidence of response to endocrine surgery (reviewed by Forrest, 1972 Stewart, Forrest, and Campbell, 1970) , they draw attention to a possible role for steroid hormones other than those of ovarian origin in the disease. Aetiocholanolone is a metabolite of dehydroepiandrosterone and its sulphate secreted by the adrenal cortex. These C-19 steroids are currently of interest in view of the demonstration that human breast cancer and other breast tissues may metabolize them.
The Tumour
If huLman breast cancer is incubated or perfused with steroid precursors carrying a radioactive label, conversion to a range of metabolites can be demonstrated (Adams and Wong, 1968; Jones, Cameron, Griffiths, Gleave, and Forrest, 1970; Jenkins and Ash, 1972) . By using different substrates one can study different steps in the steroid syntlhetic pathways and form a pattern such as that shown in figure 5 . While there is some uncertainty regarding the biosynthesis of oestrogens (Adams and Wong, 1972; Dao, Varela, and Morreal, 1972) there is no doubt that circulating DHA-sulphate, the main C-19 steroid secreted by the adrenal, can be converted to the active androgen 5a-dihydrotestosterone. Recent observations in our laboratory indicate that similar systems also are present in fibroadenomas of the breast and in normal breast tissues (Miller, Forrest, and Shivas, 1973) . In the light of this information absolute levels of circulating hormones may be less important than the ability of the tumour to synthesize growth-promoting steroids which are locally active. The recent work of Jensen and his colleagues from the Ben May Institute on oestrogen receptor activity has pinpointed another mechanism which may be concerned with the hormonal sensitivity of human breast cancer. Initially defined in the uterus of the immature rat (Jensen and Jacobson, 1960, 1962) it is now clear that high affinity binding protein is also present in the cytoplasm of human breast cancer (Jensen, 1970; Jensen et al, 1972) . This cytoplasmic receptor has been identified as an 8S protein which is believed to form part of a two-step system responsible for the uptake of oestradiol by the cell and its transport to the nucleus. Of particular importance is the relationship of this oestrogen receptor to hormone dependence; it has been reported by Jensen et al (1972) that only one of 18 human tumours without demonstrable oestrogen receptor activity were responsive to adrenalectomy or hypophysectomy.
A further relationship recently explored is that of sulphating enzymes for oestrogens. These enzymes are responsible for the conjugation of steroid with sulphate and their identification in a tumour has also been related to their hormonal responsiveness (Dao and Libby, 1968, 1972) .
It seems obvious that if we hope to unravel the role of hormones on neoplasia, more work is required on the action of hormones on the tumour cell. What other receptor mechanisms are present? Which messenger systems are involved? How do oestrogen and other hormones influence cell growth and multiplication? These are the problems which face investigators in this field and only when they are solved can we hope to explain the phenomenon first described in 1896, yet still ill understood.
